Carfilzomib: A novel agent for multiple myeloma

Journal of Pharmacy and Pharmacology

Volumn 65, Issue 8, 2013, Pages 1095-1106

  Redic, Kimberly ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

carfilzomib; multiple myeloma; proteasome inhibitor

Indexed keywords

ARRY 520; BORTEZOMIB; CARFILZOMIB; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; MIDAZOLAM; PANOBINOSTAT; POMALIDOMIDE; PREDNISONE; PROTEASOME; PROTEIN INHIBITOR; THALIDOMIDE; UNCLASSIFIED DRUG; VORINOSTAT;

ACUTE KIDNEY FAILURE; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; BLEEDING DISORDER; BLOOD TOXICITY; CANCER RECURRENCE; CARCINOGENICITY; CHEMOTHERAPY INDUCED EMESIS; CHILL; CONGESTIVE HEART FAILURE; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EMBRYOTOXICITY; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; FETOTOXICITY; FEVER; HEART ARREST; HEART ARRHYTHMIA; HEART DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERCALCEMIA; HYPESTHESIA; INJECTION SITE REACTION; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; LUNG EDEMA; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PAIN; PARESTHESIA; PATHOLOGIC FRACTURE; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PREMEDICATION; REVIEW; SALVAGE THERAPY; SIDE EFFECT; STRUCTURE ANALYSIS; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; UPPER RESPIRATORY TRACT INFECTION;

CARFILZOMIB; MULTIPLE MYELOMA; PROTEASOME INHIBITOR;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; MOLECULAR STRUCTURE; MULTIPLE MYELOMA; OLIGOPEPTIDES; PROTEASOME INHIBITORS;

EID: 84880114967     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12072     Document Type: Review

References (56)

1. Raab MS, et al. Multiple myeloma. Lancet 2009; 374: 324-339.
2. American Cancer Society. Cancer Facts & Figures 2013. Atlanta, GA: American Cancer Society, 2013.
3. Bergsagel PL,. Epidemiology, etiology, and molecular pathogenesis. In:, Anderson KC, ed. Multiple Myeloma. London: Remedica, 2003: 17-37.
4. Anderson KC, et al. NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw 2009; 7: 908-942.
5. Kyle RA, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-33.
6. Sirohi B, Powles R,. Multiple myeloma. Lancet 2004; 363: 875-887.
7. Kumar SK, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study. Leukemia 2012; 26: 149-157.
8. National Comprehensive Cancer Network clinical practice guidelines in oncology: multiple myeloma, version 1. 2012.
9. TM Prescribing Information. Onyx Pharmaceuticals, South San Francisco, CA, 2012.
10. Hanada M, et al. Epoxomicin, a new antitumor agent of microbial origin. J Antibiot (Tokyo) 1992; 45: 1746-1752.
11. Kim KB, et al. Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency. Bioorg Med Chem Lett 1999; 9: 3335-3340.
12. Meng L, et al. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res 1999; 59: 2798-2801.
13. Meng L, et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A 1999; 96: 10403-10408.
14. Groll M, et al. Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of α',β'-epoxyketone proteasome inhibitors. J Am Chem Soc 2000; 122: 1237-1238.
15. Arastu-Kapur S, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 2011; 17: 2734-2743.
16. Yang J, et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos 2011; 39: 1873-1882.
17. Demo SD, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007; 67: 6383-6391.
18. Kuhn DJ, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007; 110: 3281-3290.
19. Wang Z, et al. Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. Drug Metab Dispos 2013; 41: 230-237.
20. Kwon Y,. Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists. New York: Kluwer Academic, 2001.
21. O'Connor OA, et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009; 15: 7085-7091.
22. Badros AZ, et al. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia 2013. doi: 10.1038/leu.2013.29.
23. Alsina M, et al. A phase 1 single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res 2012; 18: 4830-4840.
24. Niesvizky R, et al. Phase (ph) 1b/2 dose-ranging study of carfilzomib (CFZ) in combination with lenalidomide (LEN) and dexamethasone (loDex) in relapsed-refractory multiple myeloma (R/R MM). Haematologica 2011; 96: S91 [Abstract P-209].
25. 2 expansion cohort of PX-171-007. Blood 2011; 118: Abstract 2930.
26. Jagannath S, et al. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2012; 12: 310-318.
27. Siegel DS, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120: 2817-2825.
28. Vij R, et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 2012; 158: 739-748.
29. Vij R, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012; 119: 5661-5670.
30. Siegel D, et al. A phase 2 study of prolonged carfilzomib therapy in patients with multiple myeloma previously enrolled in carfilzomib clinical trials [Abstract 2962]. Blood 2012; 120: Abstract 2962.
31. Singhal S, et al. Integrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis [abstract]. Blood 2011; 118: Abstract 1876.
32. Nooka A, et al. Hematologic safety data from four phase II studies of single-agent carfilzomib in relapsed and/or refractory multiple myeloma [abstract]. J Clin Oncol 2012; 30: Abstract 8086.
33. Martin T, et al. Carfilzomib is associated with a low rate of typically mild to moderate, non-dose limiting treatment-emergent peripheral neuropathy [abstract]. Haematologica 2012; 97: A1777.
34. Harvey R, et al. Carfilzomib dose and schedule need not be adjusted for baseline renal dysfunction, including patients on hemodialysis [abstract]. Haematologica 2012; 97: A1788.
35. Lonial S, et al. Cardiac and pulmonary safety profile of single-agent carfilzomib from four phase 2 studies in patients with relapsed and/or refractory multiple myeloma. Blood 2012; 120: Abstract 4037.
36. Jakubowiak AJ, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012; 120: 1801-1809.
37. Anderson KC, et al. Multiple myeloma. J Natl Compr Canc Netw 2011; 9: 1146-1183.
38. Mitsiades N, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4525-4530.
39. Korde N, et al. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients. Blood 2012; 120: Abstract 732.
40. Sonneveld P, et al. Carfilzomib combined with thalidomide and dexamethasone (CTD) is an highly effective induction and consolidation treatment in newly diagnosed patients with multiple myeloma (MM) who are transplant candidates. Blood 2012; 120: Abstract 333.
41. Mikhael J, et al. Results from the phase II dose expansion of cyclophosphamide, carfilzomib, thalidomide and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma. Blood 2012; 120: Abstract 445.
42. Kolb B, et al. Phase I/II study of carfilzomib plus melphalan-prednisone (CMP) in elderly patients with de novo multiple myeloma [abstract]. J Clin Oncol 2012; 30: Abstract 8009.
43. Palumbo A, et al. Carfilzomib, cyclophosphamide and dexamethasone (CCd) for newly diagnosed multiple myeloma (MM) patients. Blood 2012; 120: Abstract 730.
44. U. S. Food and Drug Administration. FDA Drug Safety Communication: safety review update of cancer drug Revlimid (lenalidomide) and risk of developing new types of malignancies. 2012.
45. Hajek R, et al. Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM). BMC Cancer 2012; 12: 415.
46. Usmani S, et al. Phase II study of carfilzomib (CFZ) combined with other anti-myeloma agents in relapsed-refractory multiple myeloma (RRMM)-updates on the UARK compassionate use protocol [abstract]. Blood 2011; 118: Abstract 2947.
47. Hideshima T, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006; 107: 4053-4062.
48. Shah J, et al. Phase 1/1b study of the efficacy and safety of the combination of panobinostat + carfilzomib in patients with relapsed and/or refractory multiple myeloma. Blood 2012; 120: Abstract 4081.
49. Berdeja J, et al. Phase I/II study of panobinostat and carfilzomib in patients (pts) with relapsed or refractory multiple myeloma (MM), interim phase I safety analysis. Blood 2012; 120: Abstract 4048.
50. Shah J, et al. Phase 1 study of the novel kinesin spindle protein inhibitor ARRY-520 + carfilzomib in patients with relapsed and/or refractory multiple myeloma. Blood 2012; 120: Abstract 4082.
51. Shah J, et al. A multi-center phase I/II trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma. Blood 2012; 120: Abstract 74.
52. Lendvai N, et al. Phase II study of infusional carfilzomib in patients with relapsed or refractory multiple myeloma. Blood 2012; 120: Abstract 947.
53. 2 plus 40 mg weekly dexamethasone in patients with relapsed and/or refractory (R/R) multiple myeloma. Blood 2012; 120: Abstract 4036.
54. Gu J, et al. The novel proteasome inhibitor carfilzomib (CFZ) potentiates the anti-tumor activity of chemotherapeutic agents in rituximab-chemotherapy resistant lymphoma through inducing G2/M cell cycle arrest and cell death [abstract]. Blood 2011; 118: Abstract 4970.
55. Gupta SV, et al. The novel proteasome inhibitor carfilzomib functions independently of p53 to induce potent cytotoxicity in primary chronic lymphocytic leukemia cells and a defective NF-{kappa}B response [abstract]. Blood 2011; 118: Abstract 3510.
56. Sadaka B, et al. Clinical and investigational use of proteasome inhibitors for transplant rejection. Expert Opin Investig Drugs 2011; 20: 1535-1542.